-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recently, reports indicate that a clinical trial application for tazemetostat hydrobromide tablets jointly submitted by Hutchison Medicine and Epizyme has been accepted
.
It is reported that tazemetostat is a "first-in-class" EZH2 methyltransferase inhibitor developed by Epizyme.
It is planned to be developed to treat tumors and is the first EZH2 inhibitor approved by the FDA
.
Public information shows that in August this year, Hutchison Medicine reached a cooperation with Epizyme
.
According to the agreement, Hutchison Medical will be responsible for the development and commercialization of tazemetosta in Greater China for the treatment of various blood cancers and solid tumors, including epithelioid sarcoma, follicular lymphoma and diffuse large B-cell lymphoma
.
At the same time, Hutchison Medicine will also participate in the global registration study (EZH-302 study) of the tazemetostat combined with R² program (ie Refumei + Rituximab) for the treatment of second-line follicular lymphoma developed by Epizyme, and lead it Research conducted in Greater China
.
Epizyme will receive an advance payment of US$25 million, development and regulatory milestone payments of no more than US$110 million, sales milestone payments of no more than US$175 million, and additional royalties
.
Coincidentally, on November 21, Hengrui Medicine also jointly announced with CStone Pharmaceuticals that the two parties have reached a strategic cooperation and exclusive license agreement in the Greater China region for the anti-CTLA-4 monoclonal antibody CS1002
.
According to the agreement, Hengrui Pharmaceuticals will pay CStone Pharmaceuticals a total of approximately US$200 million (approximately RMB 1.
3 billion) in advance and milestone payments, as well as royalties that are a double-digit percentage of annual net sales after the products are launched
.
CStone Pharmaceuticals will grant Hengrui Pharmaceutical the exclusive right to develop, register, produce and commercialize the anti-CTLA-4 monoclonal antibody CS1002 in the Greater China region, and the permitted use is for all human and animal diseases
.
At the same time, CStone Pharmaceuticals will retain the right to develop and commercialize the anti-CTLA-4 monoclonal antibody CS1002 outside of Greater China.
.
In addition to the above companies, according to the author's understanding, there have been many cases of cooperation between domestic and foreign pharmaceutical companies and local pharmaceutical companies in the field of anti-tumor drugs since the beginning of this year
.
Regarding the frequent cooperation between pharmaceutical companies in oncology drugs, the industry believes that this is mainly because tumor diseases have always been a major threat to human health.
In order to overcome this disease, every country is constantly increasing the research and development of anti-tumor drugs.
Due to the strength of support
.
Especially in recent years, with the continuous improvement of the innovation capabilities of local pharmaceutical companies in China, the research and development of the drug field has also begun to accelerate.
In order to further promote the research and development of new drugs and reduce input costs, cooperative research and development between pharmaceutical companies It has naturally become the general trend
.
From the current point of view, under the background of accelerating research and development of pharmaceutical companies, adding capital, influx of talents, and policy support, the proportion of innovative oncology drugs such as small molecule targeted drugs, large molecule targeted drugs, and immunotherapy has begun.
Began to increase gradually
.
The industry expects that in the future, as more and more effective and cost-effective new drugs continue to appear, the oncology drug market will further expand, and there will be more and more patients
.
.
It is reported that tazemetostat is a "first-in-class" EZH2 methyltransferase inhibitor developed by Epizyme.
It is planned to be developed to treat tumors and is the first EZH2 inhibitor approved by the FDA
.
Public information shows that in August this year, Hutchison Medicine reached a cooperation with Epizyme
.
According to the agreement, Hutchison Medical will be responsible for the development and commercialization of tazemetosta in Greater China for the treatment of various blood cancers and solid tumors, including epithelioid sarcoma, follicular lymphoma and diffuse large B-cell lymphoma
.
At the same time, Hutchison Medicine will also participate in the global registration study (EZH-302 study) of the tazemetostat combined with R² program (ie Refumei + Rituximab) for the treatment of second-line follicular lymphoma developed by Epizyme, and lead it Research conducted in Greater China
.
Epizyme will receive an advance payment of US$25 million, development and regulatory milestone payments of no more than US$110 million, sales milestone payments of no more than US$175 million, and additional royalties
.
Coincidentally, on November 21, Hengrui Medicine also jointly announced with CStone Pharmaceuticals that the two parties have reached a strategic cooperation and exclusive license agreement in the Greater China region for the anti-CTLA-4 monoclonal antibody CS1002
.
According to the agreement, Hengrui Pharmaceuticals will pay CStone Pharmaceuticals a total of approximately US$200 million (approximately RMB 1.
3 billion) in advance and milestone payments, as well as royalties that are a double-digit percentage of annual net sales after the products are launched
.
CStone Pharmaceuticals will grant Hengrui Pharmaceutical the exclusive right to develop, register, produce and commercialize the anti-CTLA-4 monoclonal antibody CS1002 in the Greater China region, and the permitted use is for all human and animal diseases
.
At the same time, CStone Pharmaceuticals will retain the right to develop and commercialize the anti-CTLA-4 monoclonal antibody CS1002 outside of Greater China.
.
In addition to the above companies, according to the author's understanding, there have been many cases of cooperation between domestic and foreign pharmaceutical companies and local pharmaceutical companies in the field of anti-tumor drugs since the beginning of this year
.
Regarding the frequent cooperation between pharmaceutical companies in oncology drugs, the industry believes that this is mainly because tumor diseases have always been a major threat to human health.
In order to overcome this disease, every country is constantly increasing the research and development of anti-tumor drugs.
Due to the strength of support
.
Especially in recent years, with the continuous improvement of the innovation capabilities of local pharmaceutical companies in China, the research and development of the drug field has also begun to accelerate.
In order to further promote the research and development of new drugs and reduce input costs, cooperative research and development between pharmaceutical companies It has naturally become the general trend
.
From the current point of view, under the background of accelerating research and development of pharmaceutical companies, adding capital, influx of talents, and policy support, the proportion of innovative oncology drugs such as small molecule targeted drugs, large molecule targeted drugs, and immunotherapy has begun.
Began to increase gradually
.
The industry expects that in the future, as more and more effective and cost-effective new drugs continue to appear, the oncology drug market will further expand, and there will be more and more patients
.
